A common variant of CDKN2A (p16) predisposes to breast cancer

被引:61
作者
Debniak, T
Górski, B
Huzarski, T
Byrski, T
Cybulski, C
Mackiewicz, A
Gozdecka-Grodecka, S
Gronwald, J
Kowalska, E
Haus, O
Grzybowska, E
Stawicka, M
Swiec, M
Urbanski, K
Niepsuj, S
Wasko, B
Gózdz, S
Wandzel, P
Szczylik, C
Surdyka, D
Rozmiarek, A
Zambrano, O
Posmyk, M
Narod, SA
Lubinski, J
机构
[1] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland
[3] Dept Canc Immunol, Poznan, Poland
[4] Dept Clin Genet, Bydgoszcz, Poland
[5] Maria Sklodowska Curie Inst, Dept Tumour Biol, Gliwice, Poland
[6] Prophylact & Epidemiol Ctr, Poznan, Poland
[7] Reg Oncol Hosp, Opole, Poland
[8] Reg Oncol Ctr, Krakow, Poland
[9] Reg Oncol Hosp, Olsztyn, Poland
[10] Reg Hosp, Rzeszow, Poland
[11] Holycross Oncol Ctr, Kielce, Poland
[12] Reg Hosp, Bielsko Biala, Poland
[13] Mil Hosp, Warsaw, Poland
[14] Reg Hosp, Lublin, Poland
[15] Reg Oncol Hosp, Zielona Gora, Poland
[16] Reg Hosp, Lodz, Poland
[17] Reg Oncol Hosp, Bialystok, Poland
关键词
D O I
10.1136/jmg.2005.031476
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: A common missense variant of the CDKN2A gene (A148T) predisposes to malignant melanoma in Poland. An association between malignant melanoma and breast cancer has been reported in several families with CDKN2A mutations, Objective: To determine whether this variant also predisposes to breast cancer. Methods: Genotyping was undertaken in 4209 cases of breast cancer, unselected for family history, from 18 hospitals throughout Poland and in 3000 controls. Results: The odds ratio ( OR) associated with the CDKN2A allele for women diagnosed with breast cancer before the age of 50 was 1.5 ( p = 0.002) and after age 50 it was 1.3 ( p = 0.2). The effect was particularly strong for patients diagnosed at or before the age of 30 ( OR = 3.8; p = 0.0002). Conclusions: CDKN2A appears to be a low penetrance breast cancer susceptibility gene in Poland. The association should be confirmed in other populations.
引用
收藏
页码:763 / 765
页数:3
相关论文
共 50 条
[31]   Telomerase activity and inactivation of the tumor suppressor gene p16 (CDKN2A) in head and neck cancer [J].
Koscielny, S ;
Dahse, R ;
Beleites, E ;
Fiedler, W .
4TH EUROPEAN CONGRESS OF OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY, VOLS 1 AND 2, 2000, :699-706
[32]   Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing [J].
Bihl, Michel P. ;
Foerster, Anja ;
Lugli, Alessandro ;
Zlobec, Inti .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[33]   Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing [J].
Michel P Bihl ;
Anja Foerster ;
Alessandro Lugli ;
Inti Zlobec .
Journal of Translational Medicine, 10
[34]   Surgical outcomes after pancreatic surgery in patients with a germline CDKN2A/p16 pathogenic variant under surveillance [J].
Onnekink, Anke M. ;
Michiels, Nynke ;
Klatte, Derk C. F. ;
Oldenburg, Lotte ;
Mieog, J. Sven D. ;
Vahrmeijer, Alexander L. ;
van Hooft, Jeanin E. ;
van Leerdam, Monique E. ;
Bonsing, Bert A. .
BRITISH JOURNAL OF SURGERY, 2024, 111 (01)
[35]   Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation [J].
Nielsen, GP ;
Stemmer-Rachamimov, AO ;
Ino, Y ;
Moller, MB ;
Rosenberg, AE ;
Louis, DN .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1879-1884
[36]   Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma [J].
Li Su ;
Hanwei Wang ;
Jingwei Miao ;
Ying Liang .
Scientific Reports, 5
[37]   Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families [J].
Emanuel Yakobson ;
Pnina Shemesh ;
Esther Azizi ;
Eyal Winkler ;
Norman Lassam ;
David Hogg ;
Sharon Brookes ;
Gordon Peters ;
Michal Lotem ;
Abraham Zlotogorski ;
Marina Landau ;
Mark Safro ;
Raphael Shafir ;
Eitan Friedman ;
Hava Peretz .
European Journal of Human Genetics, 2000, 8 :590-596
[38]   Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma [J].
Su, Li ;
Wang, Hanwei ;
Miao, Jingwei ;
Liang, Ying .
SCIENTIFIC REPORTS, 2015, 5
[39]   Absence of p16 gene (CDKN2A) deletions in HNSCC occurring in young adults [J].
O'Regan, EM ;
Sheils, OM ;
Murphy, NC ;
Ring, M ;
Toner, ME ;
Finn, SP ;
Smyth, PC ;
Cahill, S ;
O'Leary, JJ .
LABORATORY INVESTIGATION, 2005, 85 :216A-216A
[40]   Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma [J].
Padhi, Swati Shree ;
Roy, Souvick ;
Kar, Madhabananda ;
Saha, Arka ;
Roy, Shomereeta ;
Adhya, Amit ;
Baisakh, Manas ;
Banerjee, Birendranath .
ORAL ONCOLOGY, 2017, 73 :27-35